Eikon Therapeutics, Inc.
EIKN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001861123
In the last 90 days, Eikon Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 77 institutions reported holding it in 13F filings for Q2 2026, worth $344.1M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $1.03M in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +25 vs. previous quarter
- 77
- 13F valueReported value at the end of Q2 2026
- $344.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding EIKN, Q2 2026
No superinvestor reported holding EIKN at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Eikon Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 (view filing)4:33 PM ET | Sep 3 | 5 days | Svennilson Peter and 7 others10% Owner | PPurchase | +89.2K | $11.56 | +$1.03M | New position89.2K after | |
| Feb 9, 2026 (view filing)9:19 PM ET | Feb 6 | 3 days | Svennilson Peter and 7 others10% Owner | PPurchase | +2.12M | $18.00 | +$38.1M | New position1.32M after | 3 lots |
| Feb 6, 2026 (view filing)7:37 PM ET | Feb 4 | 2 days | Foresite Capital Fund IV, L.P. and 7 others10% Owner | PPurchase | +55.6K | $18.00 | +$1.00M | +4.4%1.32M after | |
| Feb 6, 2026 (view filing)6:25 PM ET | Feb 4 | 2 days | Wolfe Josh and 5 othersDirector, 10% Owner | PPurchase | +277.8K | $18.00 | +$5.00M | New position138.9K after | 2 lotsDuplicate filing |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Frazier Kenneth CDirector | PPurchase | +111.1K | $18.00 | +$2.00M | New position111.1K after | |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Wolfe JoshDirector, 10% Owner | PPurchase | +277.8K | $18.00 | +$5.00M | New position138.9K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Eikon Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 4,993,906 | $65.2M | 0.00% | +1,157,076+30.2% | Added |
| BlackRock, Inc. | 4,281,425 | $55.9M | 0.00% | +962,046+29.0% | Added |
| Foresite Capital Management IV, LLC | 1,943,682 | $25.4M | 8.74% | 00.0% | Unchanged |
| Merck & Co., Inc. | 1,666,666 | $21.7M | 4.13% | 00.0% | Unchanged |
| T. Rowe Price Investment Management, Inc. | 1,595,274 | $20.8M | 0.01% | +372,787+30.5% | Added |
| Foresite Capital Management V, LLC | 1,318,983 | $17.2M | 4.75% | 00.0% | Unchanged |
| Capital World Investors | 1,175,944 | $15.3M | 0.00% | +32,307+2.8% | Added |
| Price T Rowe Associates Inc | 1,005,035 | $13.1M | 0.00% | +29,201+3.0% | Added |
| Vanguard Capital Management LLC | 922,707 | $12.0M | 0.00% | −46,724−4.8% | Reduced |
| EcoR1 Capital, LLC | 732,606 | $9.56M | 0.47% | 00.0% | Unchanged |